The Hidden Liabilities of Using Email for Clinical Trial Communications
About: Sharing study information by email? Is it safe? Is it secure? Is it compliant? Understand the risks (and mitigate them).
Email is ubiquitous to our daily life and it is understandable that people think it's fine to share sensitive and confidential information by email. However, the perceived security of email is a mirage. Email is too easy to misuse and lacks controls on information distribution that are standard in other mission-critical clinical trial systems.
Watch clinical trial communication and technology expert, Johnny Bilotta, discuss the truth about the wild and scary world of email.
- Become better informed about the visible and hidden liabilities of email
- Make educated judgments about how you and your team use email during your clinical activities
- Consider alternative solutions to mitigate risks
- Johnny Bilotta, Vp of Product Design
- Adam Wood, VP of Business Development, myClin
myClin is the leading Clinical Trial Knowledge Platform, offering a transformative collaboration channel and the most documented, data-driven clinical trial oversight.
The company's mission is to leverage technology to enhance participation, engagement, collaboration, and compliance in clinical trials.
The team of clinical research veterans that created myClin in 2008 brought deep experience delivering clinical operations services and building feature-rich eClinical systems. Since then, myClin has been used across all phases of research, in global bio-pharmaceutical and device studies with thousands of clinical users.
myClin is headquartered in Philadelphia, PA, with offices in San Francisco, CA, and the UK.